1
|
Gregnani MF, Hungaro TG, Martins-Silva L, Bader M, Araujo RC. Bradykinin B2 Receptor Signaling Increases Glucose Uptake and Oxidation: Evidence and Open Questions. Front Pharmacol 2020; 11:1162. [PMID: 32848770 PMCID: PMC7417865 DOI: 10.3389/fphar.2020.01162] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 07/17/2020] [Indexed: 12/21/2022] Open
Abstract
The Kinin B2 receptor (B2R) is classically involved in vasodilation and inflammatory responses. However, through the observation of hypoglycemic effects of Angiotensin-I-Converting Enzyme (ACE) inhibitors, this protein has been related to metabolic glucose modulation in physiological and pathophysiological contexts. Although several studies have evaluated this matter, the different methodologies and models employed, combined with the distinct target organs, results in a challenge to summarize and apply the knowledge in this field. Therefore, this review aims to compile human and animal data in order to provide a big picture about what is already known regarding B2R and glucose metabolism, as well to suggest pending investigation issues aiming at evaluating the role of B2R in relation to glucose metabolism in homeostatic situations and metabolic disturbances. The data indicate that B2R signaling is involved mainly in glucose uptake in skeletal muscle and adipose tissue, acting as a synergic player beside insulin. However, most data indicate that B2R induces increased glucose oxidation, instead of storage, via activation of a broad signaling cascade involving Nitric Oxide (NO) and cyclic-GMP dependent protein kinase (PKG). Additionally, we highlight that this modulation is impaired in metabolic disturbances such as diabetes and obesity, and we provide a hypothetic mechanism to explain this blockade in light of literature data provided for this review, as well as other authors.
Collapse
Affiliation(s)
- Marcos Fernandes Gregnani
- Laboratory of Genetic and Metabolism of Exercise, Departamento de Biofísica, Universidade Federal de São Paulo, São Paulo, Brazil.,Max-Delbrück Center for Molecular Medicine (MDC), Berlin, Germany
| | - Talita G Hungaro
- Laboratory of Genetic and Metabolism of Exercise, Departamento de Biofísica, Universidade Federal de São Paulo, São Paulo, Brazil.,Max-Delbrück Center for Molecular Medicine (MDC), Berlin, Germany
| | | | - Michael Bader
- Max-Delbrück Center for Molecular Medicine (MDC), Berlin, Germany.,Institute for Biology, University of Lübeck, Lübeck, Germany.,Charité University Medicine, Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany
| | - Ronaldo C Araujo
- Laboratory of Genetic and Metabolism of Exercise, Departamento de Biofísica, Universidade Federal de São Paulo, São Paulo, Brazil
| |
Collapse
|
2
|
Tao YX, Liang XF. G Protein-Coupled Receptors as Regulators of Glucose Homeostasis and Therapeutic Targets for Diabetes Mellitus. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2014; 121:1-21. [DOI: 10.1016/b978-0-12-800101-1.00001-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
3
|
Barros CC, Haro A, Russo FJ, Schadock I, Almeida SS, Reis FC, Moraes MR, Haidar A, Hirata AE, Mori M, Bacurau RFP, Würtele M, Bader M, Pesquero JB, Araujo RC. Bradykinin inhibits hepatic gluconeogenesis in obese mice. J Transl Med 2012; 92:1419-27. [PMID: 22868909 DOI: 10.1038/labinvest.2012.105] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
The kallikrein-kinin system (KKS) has been previously linked to glucose homeostasis. In isolated muscle or fat cells, acute bradykinin (BK) stimulation was shown to improve insulin action and increase glucose uptake by promoting glucose transporter 4 translocation to plasma membrane. However, the role for BK in the pathophysiology of obesity and type 2 diabetes remains largely unknown. To address this, we generated genetically obese mice (ob/ob) lacking the BK B2 receptor (obB2KO). Despite similar body weight or fat accumulation, obB2KO mice showed increased fasting glycemia (162.3 ± 28.2 mg/dl vs 85.3 ± 13.3 mg/dl), hyperinsulinemia (7.71 ± 1.75 ng/ml vs 4.09 ± 0.51 ng/ml) and impaired glucose tolerance when compared with ob/ob control mice (obWT), indicating insulin resistance and impaired glucose homeostasis. This was corroborated by increased glucose production in response to a pyruvate challenge. Increased gluconeogenesis was accompanied by increased hepatic mRNA expression of forkhead box protein O1 (FoxO1, four-fold), peroxisome proliferator-activated receptor gamma co-activator 1-alpha (seven-fold), phosphoenolpyruvate carboxykinase (PEPCK, three-fold) and glucose-6-phosphatase (eight-fold). FoxO1 nuclear exclusion was also impaired, as the obB2KO mice showed increased levels of this transcription factor in the nucleus fraction of liver homogenates during random feeding. Intraportal injection of BK in lean mice was able to decrease the hepatic mRNA expression of FoxO1 and PEPCK. In conclusion, BK modulates glucose homeostasis by affecting hepatic glucose production in obWT. These results point to a protective role of the KKS in the pathophysiology of type 2 diabetes mellitus.
Collapse
|
4
|
Andrade SS, Silva-Lucca RA, Santana LA, Gouvea IE, Juliano MA, Carmona AK, Araújo MS, Sampaio MU, Oliva MLV. Biochemical characterization of a cysteine proteinase from Bauhinia forficata leaves and its kininogenase activity. Process Biochem 2011. [DOI: 10.1016/j.procbio.2010.10.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Bharate SB, Rodge A, Joshi RK, Kaur J, Srinivasan S, Kumar SS, Kulkarni-Almeida A, Balachandran S, Balakrishnan A, Vishwakarma RA. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorg Med Chem Lett 2008; 18:6357-61. [PMID: 18993064 DOI: 10.1016/j.bmcl.2008.10.085] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2008] [Revised: 09/26/2008] [Accepted: 10/20/2008] [Indexed: 10/21/2022]
Abstract
In this letter, we report discovery of diacylphloroglucinol compounds as a new class of GPR40 (FFAR1) agonists. Several diacylphloroglucinols with varying length of acyl functionality and substitution on aromatic hydroxyls were synthesized and evaluated for GPR40 agonism using functional calcium-flux assay. Out of 17 compounds evaluated, 14, 17, 19 and 25 exhibited good GPR40 agonistic activity with EC(50) values ranging from 0.07 to 8 microM (pEC(50) 7.12-5.09), respectively, with maximal agonistic response of 84-102%.
Collapse
Affiliation(s)
- Sandip B Bharate
- Department of Medicinal Chemistry, Piramal Life Sciences Limited, 1 Nirlon Complex, Off Western Express Highway, Goregaon (E), Mumbai 400063, India
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Cheng H, Yibchok-Anun S, Park SC, Hsu WH. Somatostatin-induced paradoxical increase in intracellular Ca2+ concentration and insulin release in the presence of arginine vasopressin in clonal HIT-T15 beta-cells. Biochem J 2002; 364:33-9. [PMID: 11988073 PMCID: PMC1222542 DOI: 10.1042/bj3640033] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Somatostatin, a hormone that signals via G(i)/G(o), usually inhibits increases in intracellular calcium concentration ([Ca(2+)](i)) and insulin release from beta-cells. We have found that in the presence of arginine vasopressin (AVP), which signals via G(q), somatostatin increased [Ca(2+)](i), leading to insulin release in HIT-T15 cells. The increase in [Ca(2+)](i) by somatostatin was observed even after 60 min of AVP treatment. Somatostatin alone failed to increase [Ca(2+)](i) and insulin release. Somatostatin induced changes in [Ca(2+)](i) in a biphasic pattern, characterized by a sharp and transient increase followed by a rapid decline to sub-basal levels. Pretreatment with pertussis toxin, which inactivates G(i)/G(o), abolished the effects of somatostatin. U-73122, an inhibitor of phospholipase C, antagonized the somatostatin-induced increase in [Ca(2+)](i). In Ca(2+)-free medium, somatostatin still increased [Ca(2+)](i). Depletion of intracellular Ca(2+) stores with thapsigargin, a microsomal Ca(2+)-ATPase inhibitor, abolished somatostatin's effect. In the presence of bradykinin, another G(q)-coupled receptor agonist, somatostatin also increased [Ca(2+)](i), but not in the presence of isoproterenol (a G(s)-coupled receptor agonist) or medetomidine (a G(i)/G(o)-coupled receptor agonist). Our findings suggest that somatostatin signals through G(i)/G(o), and involves phospholipase C and Ca(2+) release from the endoplasmic reticulum. The increase in [Ca(2+)](i) by somatostatin leads to insulin release. This cross-talk is specific to G(q) and G(i)/G(o), and is not limited to the AVP and somatostatin receptors.
Collapse
Affiliation(s)
- Henrique Cheng
- Department of Biomedical Sciences, Iowa State University, Ames, IA 50011-1250, USA
| | | | | | | |
Collapse
|
7
|
Damas J, Hallet C, Lefebvre PJ. Changes in blood glucose and plasma insulin levels induced by bradykinin in anaesthetized rats. Br J Pharmacol 2001; 134:1312-8. [PMID: 11704652 PMCID: PMC1573062 DOI: 10.1038/sj.bjp.0704374] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
1. The influence of bradykinin (BK) on blood glucose and plasma insulin levels was investigated in anaesthetized rats. 2. Blood glucose level was dose-dependently increased by intravenous infusion of BK. This effect of BK was enhanced by captopril, an inhibitor of angiotensin-converting enzyme (ACE). Des-Arg9-bradykinin (DABK), a kinin B1 receptor agonist, did not modify blood glucose levels while the effect of BK was inhibited by Hoe-140, a kinin B2 receptor antagonist. 3. The effect of BK was reduced by the NO-synthase inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME), and by the cyclo-oxygenase inhibitor, indomethacin. The effect of BK was suppressed by the association of propranolol with phentolamine or phenoxybenzamine. It was also reduced by hexamethonium, a ganglion-blocking drug. In adrenalectomized rats, the infusion of BK slightly decreased blood glucose levels. 4. The hyperglycaemic effect of adrenaline was suppressed by propranolol associated with phentolamine or phenoxybenzamine, but it was not modified by L-NAME. 5. Infusion of BK did not modify plasma insulin levels. However, after phentolamine and propranolol, BK induced a transient 2 fold rise in plasma insulin levels. The release of insulin was dose-dependent and inhibited by Hoe-140. 6. We conclude that infusion of BK induces, via a stimulation of B2 receptors, the release of NO and of prostanoids. The latter agents activate through a reflex pathway the release of catecholamines from the adrenal medulla. This release increases blood glucose levels and reduces plasma insulin levels. After adrenoceptor inhibition, BK induces a secretion of insulin, via the stimulation of B2 receptors.
Collapse
Affiliation(s)
- Jacques Damas
- Human Physiology, University of Liège, 17 Place Delcour, Liège B-4020, Belgium
- Author for correspondence:
| | - Claude Hallet
- Human Physiology, University of Liège, 17 Place Delcour, Liège B-4020, Belgium
| | - Pierre J Lefebvre
- Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, University of Liège, Belgium
| |
Collapse
|
8
|
|
9
|
Cheng CP, Onishi K, Ohte N, Suzuki M, Little WC. Functional Effects of Endogenous Bradykinin in Congestive Heart Failure. J Am Coll Cardiol 1998. [DOI: 10.1016/s0735-1097(98)00159-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Yang C, Hsu WH. Glucose-dependency of bradykinin-induced insulin secretion from the perfused rat pancreas. REGULATORY PEPTIDES 1997; 71:23-8. [PMID: 9299638 DOI: 10.1016/s0167-0115(97)01011-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In order to investigate the glucose dependency of bradykinin (BK)-induced insulin secretion, rat pancreata were perfused in situ with BK (1 microM) for 30 min in the presence of glucose concentrations of 0 - 20 mM. Glucose (6 mM) alone maintained a steady baseline insulin secretion which was 6.7 %/- 0.5 ng/min (n = 4). The rate of insulin secretion in the presence of 0 and 1 mM glucose was approximately 70 - 80% and approximately 60-70% less, respectively, than in the presence of 6 mM glucose. The perfusate glucose concentrations of 10 and 20 mM induced a biphasic and dose-dependent insulin secretion, characterized by a transient increase followed by a sustained phase; the sustained phase was higher than the transient increase. BK failed to change insulin secretion in the absence of extracellular glucose. When BK was administered in 1 mM glucose, it induced a transient insulin release peak which was 2.8-fold of the insulin secretion induced by 6 mM glucose, then the insulin concentrations of the effluents decreased gradually to the levels that were slightly higher than that induced by the 1 mM glucose alone, but lower than that induced by 6 mM glucose. After BK was administered in 6 mM glucose, it induced a transient insulin release peak that was 3.6-fold of the baseline level, and followed by a sustained insulin secretion phase which was approximately 50% higher than that of the 6 mM glucose control group. When BK was perfused with 10 or 20mM glucose, it induced a similar insulin secretion pattern as in the glucose alone groups. However, the combination of glucose (10 or 20 mM) and BK induced a higher transient insulin release peak, which was 7.8- and 12-fold of the baseline level, respectively. Also, the BK-glucose-induced sustained phase was higher than the transient peak. BK caused a greater potentiation of insulin secretion in 20 mM glucose than in 10 mM glucose. Taken together, our findings suggest that 1) BK requires the presence of glucose to stimulate insulin secretion and 2) BK induces insulin secretion in a glucose concentration-dependent manner; the higher the glucose concentration, the greater the potentiation in BK-induced insulin secretion.
Collapse
Affiliation(s)
- C Yang
- Department of Veterinary Physiology and Pharmacology, Iowa State University, Ames 50011, USA
| | | |
Collapse
|